Subscribe to Press Releases


Immunotherapies for Life

Y-mAbs Receives Breakthrough Therapy Designation for Naxitamab for the treatment of High Risk Neuroblastoma

The FDA has granted Y-mAbs Breakthrough Therapy designation for naxitamab, in combination with GM-CSF, for the treatment of high risk neuroblastoma
Read more


Y-mAbs enters into Sublicense for Neuroblastoma Vaccine

Y-mAbs enters into an exclusive sublicense with MabVax Therapeutics’ for its patented neuroblastoma vaccine
Read more


YmAbs Announces Phase I Omburtamab Data

Omburtamab as intraperitoneal radioimmunotherapy in desmoplastic small round cell tumor
Read more


YmAbs Announces Closing of $30 Million Extension of Private Equity Placement

Common stock placement extended to a total of $80 million as Sofinnova Ventures and Scopia Capital Management are added to Y-mAbs’ list of institutional shareholders
Read more


YmAbs Raises $50 Million in Equity Financing

Y-mAbs Therapeutics, Inc. closes $50 million in a private placement led by HBM Healthcare Investments (HBM) and supported by current shareholders
Read more